INTRODUCTION
Epstein-Barr virus (EBV), also known as human herpes virus-4, belongs to the γ-subfamily of herpes viruses. 1 Nearly 90 to 95% of the world's adult population is an asymptomatic carrier of EBV. [1] [2] [3] After initial exposure, this virus coexists within the host cells throughout the individual's life. 2 However, majority of the infected individuals rarely demonstrate any serious sequelae. Nonetheless, in a small population, the virus is implicated in development of malignancies, depending upon the geographic and immunologic variations. 1 The oncogenic potential of EBV in relation to human cancers has been validated by the International Agency for Research on Cancer and it has been labeled as a group I carcinogen. Now, we attempt discoursing on its role in epithelial carcinomas, especially oral squamous cell carcinoma (OSCC). Among the epithelial origin neoplasms, EBV has been strongly associated with nasopharyngeal carcinoma. In addition, its role has been implicated in gastric, breast, liver, and oral carcinomas. 2, 3 Nasopharyngeal carcinoma is associated with type II latency pattern of EBV, in which the viral genes expressed include EBNA-1, EBERs, LMP-1, LMP-2, and BARF0. The products of the above-mentioned genes primarily aid in immortalization of cells and replication of the viral genome. 1 Hence, to substantiate an etiologic association between the EBV and OSCC, these genes and their protein products ought to be demonstrated consistently and exclusively in the OSCC tumor cells/cell lines per se, rather than other types of sample, where latent viral DNA may also be present, resulting in false-positive data. Table 1 4-25 summarizes the various relevant original researches in relation to EBV and OSCC, assimilated from the PubMed search. Analyzing the above data, only 8 out of 22 studies showed significant association of EBV with OSCC. The values of EBV positive cases showed a wide variation, ranging from 0 to 100%, among the various populations studied. Studies from Taiwan and Japan exhibited the highest figure of EBV-positive cases. A decrease or lack of EDITORIAL 10.5005/jp-journals-10024-2028 JCDP EBV gene expression specifically in tumor cells by in situ polymerase chain reaction (PCR) or in situ hybridization methods was noted, with the exception of the study by Acharya et al. 8 Lastly, in majority of the studies, chosen samples were tumor tissue specimens, which may contain considerable number of infiltrating immune cells or oral secretions, affecting the PCR results. In addition, the immune-compromised status of the cancer patients also might lead to an increased shedding of the EBV. The pathogenesis of EBV in development of OSCC is unclear. The insignificant results of EBV DNA in OSCC with respect to control groups could be explained by the "hit and run theory," according to which the viral DNA only acts as an initiator and wanes with the malignant transformation of cells. 9 This hypothesis may be substantiated by the negative expression of LMP-1 viral protein in many cases. The LMP-1 is thought to be essential for transformation of cells and unnecessary in already-transformed cells. Other possible explanations, as previously suggested by Horiuchi et al, 25 include that viral DNA only exists as a passenger in the malignant cells or the malignant cells are vulnerable targets and get easily infected.
CONCLUSION
The role of EBV in pathogenesis of OSCC as a major etiological agent seems to be unlikely from the present available data. Studies with large number of patients, appropriate sample selection, strict inclusion criteria, and precise method of detection are critical for conclusive results.
